FDA approved fluorine-containing drugs in 2023
Chinese Chemical Letters · 2024-11 · 35 (11) · 109780
DOI: 10.1016/j.cclet.2024.109780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese Chemical Letters, 2024-11. Verfasst von Qian Wang und 7 weiteren Autor:innen. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 151 Literaturangaben. Gefördert von: Ikerbasque, Basque Foundation for Science, Qinglan Project of Jiangsu Province of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Ikerbasque, Basque Foundation for Science
- Qinglan Project of Jiangsu Province of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, Q., Bian, Y., Dhawan, G., Zhang, W., Sorochinsky, A. E., Makarem, A., Soloshonok, V. A., & Han, J. (2024). FDA approved fluorine-containing drugs in 2023. Chinese Chemical Letters, 35(11), 109780. https://doi.org/10.1016/j.cclet.2024.109780
Vancouver
Wang Q, Bian Y, Dhawan G, Zhang W, Sorochinsky AE, Makarem A, et al. FDA approved fluorine-containing drugs in 2023. Chinese Chemical Letters. 2024;35(11):109780. doi:10.1016/j.cclet.2024.109780
BibTeX
@article{Wang2024,
author = {Wang, Qian and Bian, Yeping and Dhawan, Gagan and Zhang, Wei and Sorochinsky, Alexander E. and Makarem, Ata and Soloshonok, Vadim A. and Han, Jianlin},
title = {FDA approved fluorine-containing drugs in 2023},
journal = {Chinese Chemical Letters},
year = {2024},
volume = {35},
number = {11},
pages = {109780},
doi = {10.1016/j.cclet.2024.109780}
}
EUVIMED